C
Cindy L. Schwartz
Researcher at Medical College of Wisconsin
Publications - 170
Citations - 12608
Cindy L. Schwartz is an academic researcher from Medical College of Wisconsin. The author has contributed to research in topics: Chemotherapy & Population. The author has an hindex of 43, co-authored 163 publications receiving 11100 citations. Previous affiliations of Cindy L. Schwartz include Harvard University & Children's Oncology Group.
Papers
More filters
Journal ArticleDOI
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Kevin C. Oeffinger,Ann C. Mertens,Charles A. Sklar,Toana Kawashima,Melissa M. Hudson,Anna T. Meadows,Debra L. Friedman,Neyssa Marina,Wendy L. Hobbie,Nina S. Kadan-Lottick,Cindy L. Schwartz,Wendy M. Leisenring,Leslie L. Robison +12 more
TL;DR: Survivors of childhood cancer have a high rate of illness owing to chronic health conditions, including severe, disabling, or life-threatening conditions or death due to a chronic condition.
Journal ArticleDOI
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Thomas J. Walsh,Robert W. Finberg,Carola A.S. Arndt,John W. Hiemenz,Cindy L. Schwartz,David C. Bodensteiner,Peter G. Pappas,Nita Seibel,Richard N. Greenberg,Stephen Dummer,Mindy G. Schuster,John S. Holcenberg,William E. Dismukes +12 more
TL;DR: A randomized, double-blind, multicenter trial comparing liposomal amphotericin B with conventional amphoteric in B as empirical antifungal therapy for patients with persistent fever and neutropenia.
Journal ArticleDOI
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
Joseph R. Carver,Charles L. Shapiro,Andrea K. Ng,Linda A. Jacobs,Cindy L. Schwartz,Katherine S. Virgo,Karen L. Hagerty,Mark R. Somerfield,David J. Vaughn +8 more
TL;DR: An increased incidence of cardiac and/or pulmonary dysfunction is observed in cancer survivors and research is needed to identify high-risk patients, and to determine the optimal screening strategies and subsequent treatment.
Journal ArticleDOI
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,Eugenie S. Kleinerman,Donna L. Betcher,Mark L. Bernstein,Ernest U. Conrad,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,John H. Healey,Andrew G. Huvos,Michael P. Link,Joseph Montebello,Helen Nadel,Michael Nieder,Judith K. Sato,Gene P. Siegal,Michael Weiner,Robert J. Wells,Lester E. Wold,Richard B. Womer,Holcombe E. Grier +23 more
TL;DR: The addition of MTP to chemotherapy might improve EFS, but additional clinical and laboratory investigation will be necessary to explain the interaction between ifosfamide and MTP.
Journal ArticleDOI
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,John H. Healey,Mark L. Bernstein,Donna L. Betcher,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,Eugenie S. Kleinerman,Michael P. Link,Helen Nadel,Michael Nieder,Gene P. Siegal,Michael A. Weiner,Robert J. Wells,Richard B. Womer,Holcombe E. Grier +18 more
TL;DR: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma, and the addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.